When used in this scheme, carboplatin can reduce the activity of programmed death receptor-ligand 2 (PD-L2), expressed in cancer cells, which plays a key role in their ability to evade the immune system by inhibiting T cells [74]. This evidence concerns the gene PDCD1LG2 and cancer.